New delivery systems in contraception: Vaginal rings

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4 SUPPL., 2004, Pages

  Johansson, Elof D B ^a   Sitruk Ware, Regine ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

Oral contraceptives; Progesterone releasing ring; Vaginal rings

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL PLUS ETHINYLESTRADIOL; DIMETICONE; ELCOMETRINE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NESTORONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; UNCLASSIFIED DRUG;

BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONAL CONTRACEPTION; HORMONE BLOOD LEVEL; HUMAN; MENSTRUATION; NAUSEA; OVULATION INHIBITION; PHARMACEUTICAL CARE; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SPOTTING; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; UTERINE CERVIX CYTOLOGY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA RING; VOMITING; WITHDRAWAL BLEEDING;

EID: 2342423510     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.01.056     Document Type: Article

References (24)

1. Ahrén T, Victor A, Lithell H, Johansson EDB. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring: I, carbohydrate metabolism and liver function. Contraception 1981;24:415-27.
2. Bounds W, Szarewski A, Lowe D, Guillebaud J. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 1993;48:123-5.
3. Holmgren P-A, Lindskog M, von Schoultz B. Vaginal rings for continuous low-dose release of estradiol in the treatment of urogenital atrophy. Maturitas 1989;11:55-63.
4. Sivin I, Díaz S, Croxatto HB, Miranda P, Shaaban M, Sayed EH, et al. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380 A IUD. Contraception 1997;55:225-32.
5. Zegers-Hochschild F, Balmaceda JP, Fabres C, Alam V, Mackenna A, Fernandez E, et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for in vitro fertilization and oocyte donation. Hum Reprod 2000;10:2093-7.
6. Titia M, Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865-70.
7. Alvarez-Sanchez F, Brache V, Jackanicz T, Faundes A. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception 1992;46:387-98.
8. Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65:629-36.
9. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks and benefits. Menopause 2002;9:6-15.
10. Jackanicz TM. Vaginal rings for delivery of Nestorone progestin for contraception. Eur J Contracept Reprod Health Care 2000;5:38.
11. Harwood B, Mishell DR Jr. Contraceptive vaginal rings. Semin Reprod Med 2001;19:381-90.
12. Massai R, Diaz S, Jackanicz T, Croxatto HB. Vaginal rings for contraception in lactating women. Steroids 2000;65:703-7.
13. Laurikka-Routti M, Haukkanaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 1990;42:111-20.
14. Lahteenmaki P, Jukarainen H. Novel delivery systems in contraception. Br Med Bull 2000;56:739-48.
15. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol. Hum Reprod 2001;16:469-75.
16. Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 1999;59:311-8.
17. Weisberg E, Fraser IS, Mishell DR Jr, Lacarra M, Darney P, Jackanicz TM. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception 1999;59:305-10.
18. Brache V, Mishell DR, Lahteemaki P, Alvarez F, Elomaa K, Jackanicz T, et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception 2001;63:257-61.
19. Hatcher RA, et al. Contraceptive technology. 17th rev ed. New York: Ardent Media; 1998.
20. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233-42.
21. Fraser IS, Lacarra M, Mishell DR, Alvarez F, Brache V, Lahteenmaki P, et al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 2000;61:131-8.
22. Fraser IS, Lahteenmaki P, Elomaa K, Lacarra M, Mishell DR Jr, Alvarez F, et al. Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active women. Hum Reprod 1999;14:1974-8.
23. Ballagh SA, Mishell DR Jr, Lacarra M, Shoupe D, Jackanicz TM, Eggena P. Contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol. Contraception 1994;50:517-33.
24. Tuba Z, Bardin CW, Dancsi A, Francsics-Czinege E, Molnar C, Csorgei J, et al. Synthesis and biological activity of a new progestogen, 16-methylene-17alpha-hydroxy-18-methyl-19-norpregn-4-ene-3, 20 dione acetate. Steroids 2000;65:266-74.